

AUG 26 1999

Product Performance and Substantial Equivalency

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: K992395

Submitter: SeraCare Technology, Inc. DBA Consolidated Technologies
2170 Woodward Street
Austin, TX 78744-1832
Phone: (512) 445-5100
Fax: (512) 445-5515

Contact: Rusty Sewell

Preparation date: July 13, 1999

Product name (trade & common):

Proprietary: Urine Drug Screening Control

Common: Not Applicable

Classification name:

Class I, Product code: DIF

21 CFR 862.3280 : Quality Control Material (Assayed and Unassayed)

Predicate device:

LIQUICHEK™ URINE TOXICOLOGY CONTROLS

BIO-RAD Laboratories

K-971691

Device description:

Urine Drug Screening Control is designed to monitor the performance of screening, semi-quantitative and confirmatory drugs-of-abuse testing procedures.

Purified drugs or drug metabolites added to a human urine based matrix to provide a stable liquid control, which closely mimics drug containing human urine. The product contains <0.1% sodium azide as a preservative.

Intended use:

Urine Drug Screening Control is a liquid human urine based assayed quality control material intended to monitor and evaluate the precision and the accuracy of laboratory testing procedures for the analytes listed in the package insert.

Labeling:

Vial labels see Attachment I

Secondary Container label, see Attachment II

Package Insert, see Attachment III

510(k) Summary (continued)**Comparative analysis:**

The table below provides a summary of the technological characteristics between Urine Drug Screening Control and the predicate device.

Device Characteristic	Urine Drug Screening Control	LIQUICHEK Urine Toxicology Controls
Intended use	Assayed control for monitoring urine assays for drugs of abuse	Assayed control for monitoring urine assays for drugs of abuse
Matrix	Human Urine	Human Urine
Form	Liquid	Liquid
Analytes	Common abused drugs	Common abused drugs
Storage	2-8°C	2-8°C
Stability	30 days at 2-8°C, open (See Note)	30 days at 2-8°C, open

Note: Based on accelerated stability. Real time stability studies currently in progress

Conclusions:

The information provided in the pre-market notification demonstrates that Urine Drug Screening Control is substantially equivalent to the predicate device, for which there is FDA clearance. This equivalence was demonstrated through comparison of intended uses and physical properties to a commercially available device. The information supplied in the pre-market notification provides reasonable assurance that Urine Drug Screening Control is safe and effective for the stated intended use.



DEPARTMENT OF HEALTH & HUMAN SERVICES

AUG 26 1999

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Mr. Rusty Sewell
Product Development Engineer
SeraCare Technology, Inc.
DBA, Consolidated Technologies
2170 Woodward Street
Austin, Texas 78744-1832

Re: K992395
Trade Name: Urine Drug Screening Control
Regulatory Class: I
Product Code: DIF
Dated: July 13, 1999
Received: July 19, 1999

Dear Mr. Sewell:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.

A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

510(k) number (if known): K 99 2395

Device name: Urine Drug Screening Control

Indications for use:

Urine Drug Screening Control is a liquid human urine based assayed quality control material intended to monitor the performance of screening, semi-quantitative and confirmatory drug-of-abuse testing procedures.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number

992395

Prescription ✓